Please enable JS

About

Corporate Overview

Momenta is a biotechnology company with a validated innovative disease analytics platform. Our scientific foundation is a set of tools and methods that allow us to develop a deep understanding of the links between a compound’s chemical structure, biological function and its manufacturing process. We are applying our innovative technology to the discovery and development of novel therapeutics for immune-mediated diseases with high unmet need.  Momenta also has a focused pipeline of two biosimilar candidates: M923, Momenta’s wholly-owned proposed biosimilar to HUMIRA®, and M710, a proposed biosimilar to EYLEA® being developed in collaboration with Mylan.  

  • In 2010, we validated our approach to the development of highly complex molecules by becoming the first company to achieve U.S. regulatory approval of a generic version of LOVENOX® (enoxaparin sodium injection) for the treatment of deep vein thrombosis (DVT).
  • In 2015, we and Sandoz received U.S. regulatory approval for and launched our second complex generic, Glatopa®  20 mg (glatiramer acetate injection), a fully substitutable generic version of daily COPAXONE® 20 mg.  Glatopa 20 mg was the first approved generic drug available for the treatment of patients with relapsing-forms of multiple sclerosis.
  • In 2018, we and Sandoz received FDA approval of their Abbreviated New Drug Application for a three times weekly COPAXONE® 40mg/mL (glatiramer acetate injection).
  • Today, Momenta’s development pipeline  is focused on discovering and developing novel therapeutics to treat rare, immune-mediated diseases. Momenta’s goal is to continue pushing our science forward to develop products that create value for patients, our healthcare system and our shareholders.

 

History

Momenta was founded in 2001 based on technology discovered and developed at the Massachusetts Institute of Technology (MIT) for the precise sequencing of complex sugar molecules. Early efforts to explore the biological role of sugars were constrained by the absence of tools to fully analyze complex sugars. The initial methods to characterize sugar molecules were discovered by two of our founders, Ram Sasisekharan, Ph.D., Professor of Biological Engineering, MIT, and Ganesh V. Kaundinya, Ph.D.. Early work by Dr. Sasisekharan, a molecular biologist, in collaboration with Dr. Robert Langer, a world-renowned professor at MIT, overcame many technical obstacles to clone the first heparinase, an enzyme that cuts sugar sequences into smaller components. Shortly thereafter, Dr. Kaundinya and Dr. Sasisekharan began collaborating to create a collection of enzymes and chemicals to cut sugar sequences at precise locations and then to address quantitative approaches for capturing the diversity of complex sugars. They developed improvements to conventional analytical methodologies and created a novel numerical system to describe the myriad permutations of building blocks contained in complex sugars. This early work laid the scientific foundation for our innovative characterization technology. Some of their key publications are available online.

 

LOVENOX® is a registered trademark of Sanofi-Aventis. COPAXONE® is a registered trademark of Teva Pharmaceutical Industries Ltd. Glatopa® is a registered trademark of Novartis AG. Enoxaparin Sodium Injection and Glatopa were developed under a collaboration agreement between Momenta and Sandoz. Both products are marketed under the Sandoz brand. EYLEA® (aflibercept) is a registered trademark of Regeneron Pharmaceuticals, Inc.

Last Updated 5/22/19